Eli Lilly and Company (NYSE: LLY) was highlighted by Jim Cramer as a standout biotech stock, with Cramer stating that “there’s Eli Lilly and there’s everybody else.” The company develops medicines for various conditions, including diabetes and cancer, and reported strong GLP-1 revenue that exceeded Wall Street expectations.

While Eli Lilly (LLY) has investment potential, some believe that certain AI stocks offer greater upside with less downside risk. A report on undervalued AI stocks that could benefit from Trump-era tariffs is available for those seeking alternative investment opportunities.

Overall, Eli Lilly (LLY) remains a solid choice for investors, particularly due to its success in the biotech sector. The company’s financial performance, especially in the GLP-1 complex, has impressed analysts and investors alike.

Read more at Yahoo Finance: Jim Cramer Says “Look, in the End, There’s Eli Lilly and There’s Everybody Else”